Jiangsu Yew Pharmaceutical Co., Ltd.

Jiangsu Yew Pharmaceutical Co., Ltd. is one part of the HOdo group. The factory is built by 42,000 square meters, according with the cGMP standard. The total investment is above USD 30 million. Currently we has a paclitaxel-based anti-tumor series product line, including paclitaxel, docetaxel, cabazitaxel,10-DAB, oxaliplatin, ramosetron hydrochloric acid, allopurinol, praziquantel etc. We become China's leading high-tech enterprises in the field of taxus, from cultivation of yew, paclitaxel extracting, paclitaxel purification process and paclitaxel injection. The production capacity of paclitaxel API is 300kgs annually. The product allopurinol occupied the sales share of 80% in China, also export large quantity as well. We built with our own academy, inviting overseas doctors to develop new products, to ensure product innovation. Now we have more than 20 senior specialists, to develop new products each year. Our paclitaxel was listed on U.S. FDA, the DMF registration number is 25759, and also registered in South Korea, India, Belarus and other countries. The series products are exported to Canada, Belarus, Korea, Europe and other countries and regions, with high reputation.